Figure 9. Validation of the immunotherapeutic predictive value of FOXM1. (A) Kaplan–Meier OS curves for patients with FOXM1 high and low expression subgroups in IMvigor 210 cohort. (B) FOXM1 expression was higher in responders than that in non-responders. (C) The proportion of patients with response to anti- PD-L1 therapy in FOXM1 high and low expression groups. p < 0.05 was considered significant.